🧬 A Brief Summary of Enhanced Natural Killer Cells as a New Weapon Against Cancer
A research team from Stanford University has succeeded in developing a new type of Natural Killer cells genetically modified to become able to infiltrate solid tumors and attack cancer cells more effectively. These customized immune cells show superior ability to stop the growth of multiple types of tumors in animal models, with the potential to be produced in large quantities for broad therapeutic uses.
🩺 Introduction: The Challenges of Treating Solid Tumors Through Immunity
Immune system-based therapies are among the most important advances in treating some types of cancer, especially blood and lymphatic system tumors. However, solid tumors such as skin, lung, and oral tumors remain resistant to these therapies because of the difficulty of immune cells reaching the depths of cancerous tissues.
These tumors produce chemical signals that disrupt the functions of nearby immune cells, strengthening the barrier of resistance to immunotherapy.
🧠 Natural Killer Cells: The Immune System’s Rapid Fighters
Natural Killer cells are defined as white blood cells distinguished by their innate ability to quickly recognize and eliminate abnormal cells, such as cancer cells and virus-infected cells, without prior training or specific target tolerance.
These cells differ from other white blood cells such as B and T cells, which rely on a directed and specific response.
🧪 Converting Natural Killer Cells into Effective Tissue-Resident Cells
In the new study, the research team aimed to modify Natural Killer cells so that they would become a specific type called tissue resident, which are effective cells able to remain within tissues and enter solid tumors more effectively.
The researchers conducted experiments on cells taken from the blood of human donors, where these cells were exposed to a group of cellular signals, especially the TGF-β (transforming growth factor beta) compound, which is a protein secreted by cancer cells.
🌱 The Role of TGF-β Signals in Developing Effective Cells
- The exact amount and duration of the TGF-β signal play a crucial role.
- A moderate dose of TGF-β stimulates the transformation of Natural Killer cells into tissue-resident cells with strong cancer-killing activity.
- Long or intense exposure to TGF-β leads to weak and ineffective cells, despite being tissue resident.
Experiments also showed that direct contact with temporary human tumor cells produced stronger activation compared with indirect exposure, suggesting the importance of physical interactive signals in addition to chemical signals.
🧬 The Difference Between Cytotoxic and Inhibitory Tissue-Resident Natural Killer Cells
When comparing the different models of tissue-resident Natural Killer cells, the distinctive feature of the highly active cells stood out in terms of the presence of certain molecular surface markers such as CD49a and CD103, in addition to the unique marker CD39 in cytotoxic cells.
These cells also contain proteins that enable them to kill target cells such as perforin, which punches holes in tumor cells, and granzyme A, toxic molecules that enter through these holes to kill the cells.
🩺 Encouraging Experimental Results: Slowing Tumor Growth in Animal Models
Laboratory experiments showed that the modified cells can actually infiltrate solid tumors grown in dishes — defined as tumor organoids — and succeeded in moving into the tumor tissue.
In experiments using mice, the modified cells slowed the growth of several types of tumors, including melanoma and squamous cell carcinoma of the head and neck.
🧪 Enhancement with Monoclonal Antibodies
The study showed that combining modified Natural Killer cells with treatment using cetuximab, a monoclonal antibody that targets certain cancer cells, significantly enhanced the treatment effect over more than a month.
This combination led to stronger tumor growth inhibition than either treatment alone, with no clear negative effects observed on the animals’ health.
🧪 The Possibility of Making a “Shelf-Ready” Drug
A distinctive advantage of Natural Killer cells is their low compatibility with triggering immune reactions when transferred between donors and other people, which means they can be manufactured in batches and frozen as a medical product available “off the shelf.”
The researchers say that about 20 therapeutic doses can be produced from cells taken from a single donor within two weeks, which could greatly accelerate and expand the scope of treatment compared with therapies that rely on the patient’s own cells.
🧠 Translating Research into the Clinical Stage
Preparations are underway to begin a phase one clinical trial on patients with advanced squamous cell carcinoma, to test the effectiveness and safety of using these modified cells in coordination with antibody therapy.
The trial will begin immediately upon receiving approval from the U.S. Food and Drug Administration (FDA).
🩺 Conclusion: A Promising Future for Treating Solid Tumors
This study points to a qualitative advance in the field of cancer immunotherapies. Enhanced tissue-resident Natural Killer cells may provide an effective solution to the problem of solid tumors resisting therapies.
With the possibility of producing and storing them on a large scale, they open the door to easier and faster therapeutic applications while awaiting the completion of clinical trials.
📚 Related articles
Discover more from Mohdbali
Subscribe to get the latest posts sent to your email.
